Avecho Biotechnology

About AVE

Avecho Biotechnology Limited (AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Find out what a historical investment in Avecho Biotechnology would be worth today using our AVE stock calculator.

Market Capitalisation

$46.36M

Price-earnings ratio

-7.86

Dividend yield

-

High today

$0.01

Low today

$0.01

Open price

$0.01

52-week high

-

52-week low

-

Ready to start your investing journey with Stake?

Open an account

Announcements




What does Avecho Biotechnology Limited (AVE) do?

Health products for humans and animals. But mostly humans. 

Avecho Biotechnology Limited is a Melbourne-based biotechnology company. The majority of its products are in development, but the basis of them all is its proprietary TPM (Tocopherol Phosphate Mixture) drug delivery system. TPM is a derivative of Vitamin E and “is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients”.

Avecho’s current priority for the human health market is to finalise the development of its Cannabidiol (CBD) soft-gel product, and the supporting Chemistry, Manufacturing and Control (CMC) work required for approval by the Therapeutic Goods Administration (TGA) or U.S. Food and Drug Administration (FDA). Another focus is developing products that enhance livestock feeding efficiency and health.

In October 2021, Avecho announced a collaboration with the Lambert Initiative, a long-term research program at the University of Sydney exploring the potential of cannabis in medications.

How does Avecho Technology make money?

Avecho operates in three business segments: Production, Human Health and a segment called All Other.

The Production segment sees revenue primarily from the manufacturing and sale of TPM and another TPM based product, Vital ET. Sales are made at a fixed fee per kilogram to a specialty chemical company, Ashland, for use in the global personal care industry.

As the majority of Avecho’s products are still in development, the company does not earn revenue from the Human Health and All Other segments at this time.

Is Avecho Biotechnology a profitable company?

No, the company is not profitable at this time. 

Since FY2012, the company has only recorded net losses, with FY2019’s positive income of A$849.96k being the exception. In FY2020 and FY2021, Avecho recorded net losses of A$2.63m and A$3.42m, respectively.

Avecho has continued to operate by issuing more shares and options. In February 2021, the company issued A$4.765m worth of stock at A$0.022 per share to “sophisticated investors.” It also issued 115m listed options to the same investors as well as 7.5m more listed options to the brokers.

As of April 2022, the company holds A$3.265m of cash on its books.

Is AVE stock a buy?

On 1 March 2022, the company announced the commencement of patient dosing to examine if its topically applied CBD can relieve the symptoms of osteoarthritis. 

By the end of the month, the company announced positive results with the study demonstrating “significant improvements in hand pain, hand functionality, grip strength, finger stiffness and anxiety”.

Consequently, the AVE stock price skyrocketed almost 65% from A$0.013 to A$0.02 but by the end of April had dropped off 15% to A$0.017.

As the company has a history of poor earnings, some investors would argue AVE stock makes a good speculative short-term trade but not a long-term investment.

Does AVE stock pay dividends?

Avecho Biotechnology paid dividends back in FY2009 and FY2010 but has not since then. The company has not made any announcements to do so for this financial year or the future.

Who owns AVE stock?

Holding 67.2% of the total float, the general public owns the majority of AVE stock. Individual insiders hold 21.9%.

AVE stock’s biggest owners include Mark Kerr (8.52%), Ross Copeland (5.04%), Melbourne Securities Corporation Ltd (3.23%), Paradyce Pty. Ltd (2.1%), Servbond Pty Ltd (1.31%), ACK Pty Ltd (1.12%), Wayne Kent (1.09%), Tony Amato (1.06%) and Churchcourt Pty Limited (1.04%).

Individual insiders with the most significant holdings include Chief Operating Officer Roksan Libanaki (0.6%), Chief Executive Officer Paul Gavin (0.59%), Chairman Gregory Collier (0.11%) and Non-Executive Director Ross Murdoch (0.091%).

How do I buy AVE stock?

Stake offers a quick and easy way to purchase AVE shares – along with 2,000+ other Australian stocks and ASX ETFs – for a brokerage fee of only A$3.

Stake is CHESS sponsored, meaning that when you invest in Australian shares, you get a HIN (Holder Identification Number) and stocks are held in your name.

With Stake, you can be in the market in under 5 minutes, whether it's the ASX or Wall St. If you’re interested in building your portfolio by adding AVE, sign up today.

Buying AVE shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Avecho Biotechnology in minutes.
  1. Sign up with some I.D. and zero paperwork
  2. Add funds to your account
  3. Make your first investment in AVE

The ticker symbol for Avecho Biotechnology is AVE.

One share of AVE is valued at $0.01 as of 21 November 2026.

As of 21 November 2026 Avecho Biotechnology has a market cap of $46.36M.

The Price to Earnings ratio of AVE is -7.86.

The Earnings Per Share of AVE is -$0.00.

The Avecho Biotechnology 52-week high stock price is $NaN.

The Avecho Biotechnology 52-week low stock price is $NaN.

Yes, the Stake investing platform allows you to buy AVE shares and over 13,000 more stocks and ETFs across the ASX and Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Stake app

Invest in AVE on Stake

  • Buy AVE from A$3 brokerage
  • Invest in 2,500+ Aussie stocks and ETFs
  • CHESS-sponsored ASX trades
Get started

Stock shown for demonstrative purposes only. A$3 brokerage up to A$30,000.

Explore Stake


Made in Australia

Sydney, Australia


Get the app

Scan QR code to download the app

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services Guide, Terms & Conditions, Privacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

This information is being provided in connection with the Australian retail offer component of the initial public offering of shares of Class A common stock (“Shares”) in Anthropic, PBC (“Anthropic”) (“IPO”). The Australian retail offer is an offer of newly issued Shares by Anthropic (“Australian Retail Offer”) made under the Australian prospectus lodged with the Australian Securities and Investments Commission on 11 November 2026 (“Australian Prospectus”). This information does not form part of the Australian Prospectus, and anyone considering applying for Shares under the Australian Retail Offer should rely only on information in the Australian Prospectus and any supplementary or replacement Australian Prospectus. A copy of the Australian Prospectus is available on ipo.anthropic.com. Further information about Anthropic, the IPO, the Shares and the risks of investing in Anthropic is set out in the Australian Prospectus. Anyone considering applying for Shares under the Australian Retail Offer should read and consider the Australian Prospectus in full in deciding whether to acquire Shares under the Australian Retail Offer. Anyone who wants to acquire Shares under the Australian Retail Offer will need to complete the application form that accompanies the Australian Prospectus, in accordance with the process set out in the Australian Prospectus and any other instructions from their broker. Anthropic has applied to list its Class A common stock on the Nasdaq Global Select Market under the symbol “ANT”. Anthropic will not be applying for listing on the Australian Securities Exchange.

Us securities law disclaimer

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to its acceptance after the effective date. The prospectus in the registration statement and other documents Anthropic has filed with the SEC include additional information about Anthropic and the offering. Investors may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. The registration statement (including the US prospectus) is available at www.sec.gov

Copyright © 2026 Stake. All rights reserved.